Orphan Drugs Market is projected to increase at a CAGR of 12.10% during 2017 to 2025

1
Disease Type - Oncology, Gastrointestinal,
Pulmonary, Neurology, Hematology, Cardiovascular,
Metabolic disorders, Endocrinology, and
Infectious diseases Product Type - Biologic and
Non-biologic Distribution Channel - Hospital
Pharmacies, Specialty Pharmacies, Retail
Pharmacies, and othersForecast From 2017 - 2025
Orphan Drugs Market
2
Table of Content
Sr. No. Content
Chapter 1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary
Chapter 4 Market Overview
Chapter 5 Global Orphan Drugs Market Analysis and Forecasts, By Disease Type
Chapter 6 Global Orphan Drugs Market Analysis and Forecasts, By Product Type
Chapter 7 Global Orphan Drugs Market Analysis and Forecasts, By Distribution Channel
Chapter 8 Global Orphan Drugs Market Analysis and Forecasts, By Region
Chapter 9 North America Orphan Drugs Market Analysis and Forecast
Chapter 10 Europe Orphan Drugs Market Analysis and Forecast
Chapter 11 Rest of the World Orphan Drugs Market Analysis and Forecast
Chapter 12 Country Snippets
Chapter 13 Competition Landscape
3
Orphan Drugs Market Snapshot

• Orphan drug products are medicines for the
  therapy of life-threating or extremely severe
  illnesses or disorders which are uncommon for
  diagnosis, prevention or therapy.
• Increasing importance being given to research and
  development activities is projected to swell up
  the global orphan drug market
• orphan drugs market is segmented by the disease
  type, by indicator, and by technology for study.

4
(No Transcript)
5
Reports Highlights

• The global orphan drug market is projected to
  increase at a CAGR of 12.10 during the forecast
  period 2017 to 2025. The global orphan drug
  market is expected to achieve a net valuation of
  US318.5bn by the end of 2025.
• Key Players Novartis AG, F. Hoffmann-La Roche
  Ltd., Bristol-Myers Squibb Company,
  GlaxoSmithKline plc., Daiichi Sankyo Company
  Limited, Novo Nordisk A/S, Bayer AG, AstraZeneca
  plc., and Amgen Inc., among several others.

Request Sample
6
(No Transcript)